Stratification of amyotrophic lateral sclerosis patients: A crowdsourcing approach

Robert Kueffner*, Neta Zach*, Maya Bronfeld, Raquel Norel, Nazem Atassi, Venkat Balagurusamy, Barbara Di Camillo, Adriano Chio, Merit Cudkowicz, Donna Dillenberger, Javier Garcia-Garcia, Orla Hardiman, Bruce Hoff, Joshua Knight, Melanie L. Leitner, Guang Li, Lara Mangravite, Thea Norman, Liuxia Wang, The ALS Stratification Consortium, includingWing Chung Wong, Jinfeng Xiao, Wen Chieh Fang, Jian Peng, Chen Yang, Huan Jui Chang, Gustavo Stolovitzky

*Corresponding author for this work

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

52 Citations (Scopus)
40 Downloads (CityUHK Scholars)

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease where substantial heterogeneity in clinical presentation urgently requires a better stratification of patients for the development of drug trials and clinical care. In this study we explored stratification through a crowdsourcing approach, the DREAM Prize4Life ALS Stratification Challenge. Using data from >10,000 patients from ALS clinical trials and 1479 patients from community-based patient registers, more than 30 teams developed new approaches for machine learning and clustering, outperforming the best current predictions of disease outcome. We propose a new method to integrate and analyze patient clusters across methods, showing a clear pattern of consistent and clinically relevant sub-groups of patients that also enabled the reliable classification of new patients. Our analyses reveal novel insights in ALS and describe for the first time the potential of a crowdsourcing to uncover hidden patient sub-populations, and to accelerate disease understanding and therapeutic development.

© The Author(s) 2019
Original languageEnglish
Article number690
JournalScientific Reports
Volume9
Online published24 Jan 2019
DOIs
Publication statusPublished - 2019

Funding

We are grateful to the following people for their important assistance with this manuscript: The clinicians and researchers behind the Irish and Italian ALS registers and the pharmaceutical companies which provided data to the PRO-ACT dataset, that enabled this entire endeavor, the hundreds of participants on the crowdfunding effort that provided this challenge’s award. Prof. David Schoenfeld for his assistance with statistical considerations, and, of course, the solvers who participated in the challenge and the patients who inspired this effort. Data used in the preparation of this article were obtained from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Database. As such, the following organizations and individuals within the PRO-ACT Consortium contributed to the design and implementation of the PRO-ACT Database and/or provided data, but did not participate in the analysis of the data or the writing of this report: Neurological Clinical Research Institute at MGH, Northeast ALS Consortium, Novartis, Prize4Life Israel, Regeneron Pharmaceuticals Inc., Sanofi, Teva Pharmaceutical Industries Ltd.

Publisher's Copyright Statement

  • This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

Fingerprint

Dive into the research topics of 'Stratification of amyotrophic lateral sclerosis patients: A crowdsourcing approach'. Together they form a unique fingerprint.

Cite this